drugset / Trial / NCT00664521
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to assess the safety and tolerability of combined treatment with atacicept and rituximab in subjects with active rheumatoid arthritis (RA) receiving re-treatment with rituximab.
Timeline
- Start
- 2008-03
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atacicept | Protein / enzyme biologic | 150 mg | Subcutaneous |
| Background | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |